Leishmania donovani exploits host deubiquitinating enzyme A20, a negative regulator of TLR signaling, to subvert host immune response.
TLRs, which form an interface between mammalian host and microbe, play a key role in pathogen recognition and initiation of proinflammatory response thus stimulating antimicrobial activity and host survival. However, certain intracellular pathogens such as Leishmania can successfully manipulate the TLR signaling, thus hijacking the defensive strategies of the host. Despite the presence of lipophosphoglycan, a TLR2 ligand capable of eliciting host-defensive cytokine response, on the surface of Leishmania, the strategies adopted by the parasite to silence the TLR2-mediated proinflammatory response is not understood. In this study, we showed that Leishmania donovani modulates the TLR2-mediated pathway in macrophages through inhibition of the IKK-NF-κB cascade and suppression of IL-12 and TNF-α production. This may be due to impairment of the association of TRAF6 with the TAK-TAB complex, thus inhibiting the recruitment of TRAF6 in TLR2 signaling. L. donovani infection drastically reduced Lys 63-linked ubiquitination of TRAF6, and the deubiquitinating enzyme A20 was found to be significantly upregulated in infected macrophages. Small interfering RNA-mediated silencing of A20 restored the Lys 63-linked ubiquitination of TRAF6 as well as IL-12 and TNF-α levels with a concomitant decrease in IL-10 and TGF-β synthesis in infected macrophages. Knockdown of A20 led to lower parasite survival within macrophages. Moreover, in vivo silencing of A20 by short hairpin RNA in BALB/c mice led to increased NF-κB DNA binding and host-protective proinflammatory cytokine response resulting in effective parasite clearance. These results suggest that L. donovani might exploit host A20 to inhibit the TLR2-mediated proinflammatory gene expression, thus escaping the immune responses of the host.
Indian Institute of Chemical Biology, Kolkata, India.
Supriya
S
Srivastav
Susanta
S
Kar
Ajit G
AG
Chande
Robin
R
Mukhopadhyaya
Pijush K
PK
Das
D048868:Adaptor Proteins, Signal Transducing / Q000037:antagonists & inhibitors; D000818:Animals; D002460:Cell Line; D003546:Cysteine Endopeptidases / Q000502:physiology*; D015536:Down-Regulation / Q000276:immunology*; D005260:Female; D006028:Glycosphingolipids / Q000037:antagonists & inhibitors / Q000502:physiology*; D057809:HEK293 Cells; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D007893:Leishmania donovani / Q000276:immunology* / Q000472:pathogenicity; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors; D008264:Macrophages / Q000201:enzymology / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D015398:Signal Transduction / Q000276:immunology*; D048029:TNF Receptor-Associated Factor 6 / Q000037:antagonists & inhibitors / Q000378:metabolism; D051195:Toll-Like Receptor 2 / Q000037:antagonists & inhibitors* / Q000502:physiology; D000072598:Tumor Necrosis Factor alpha-Induced Protein 3; D000099151:MAP Kinase Kinase Kinase 7
D048868:Adaptor Proteins, Signal Transducing; D003546:Cysteine Endopeptidases; D006028:Glycosphingolipids; D047908:Intracellular Signaling Peptides and Proteins; D020930:MAP Kinase Kinase Kinases; D048029:TNF Receptor-Associated Factor 6; D051195:Toll-Like Receptor 2; D000072598:Tumor Necrosis Factor alpha-Induced Protein 3; D000099151:MAP Kinase Kinase Kinase 7; C498761:Tab2 protein, mouse; C493486:Tlr2 protein, mouse; C008290:lipophosphonoglycan; C513261:Tnfaip3 protein, mouse